New treatment approaches for improving CMML-associated cytopenias or targeting the CMML malignant clone are emerging. More than 25 therapeutic agents are currently being evaluated in phase 1 or phase 2 clinical trials for CMML and other myeloid malignancies, often in combination with a HMA backbone....
A number of DNMT inhibitors (DNMTi) are already in clinical use or currently under investigation in clinical trials. The pyrimidine nucleoside analogues azacitidine (5-azacytidine, Vidaza®) and decitabine (5-aza-2′deoxycytidine, Dacogen®) are approved by the US Food and Drug Administration (...
Small-molecule splicing modulators are currently in clinical trials and, in addition to splice site-switching antisense oligonucleotides, offer the promise of novel and personalized approaches to cancer treatment. Key points Alternative splicing enables the generation of distinct mRNA and protein isoforms ...
Brian Hill, MD, PhD: The long-term treatment outcomes for patients treated with CAR T [chimeric antigen-receptor T-cell] therapy are very impressive in the sense that historically we knew that these patients really had very limited overall survival. What we can see in some of the long-term...
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care View More Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials View More Cases & Conversations™: Integrating Novel Approaches...
In clinical trials, it has been used in solid tumors, such as lung and breast cancer and metastatic melanoma, and in hematological malignancies, as CML, AML, CMML, and Hodgkin disease. MGCD 0103 is a more recent benzamide that shows selectivity for HDAC I/II. It has been used in ...
Table 2. Eligibility criteria of phase 2 and 3 trials of oral decitabine/cedazuridine CharacteristicPhase 2 (NCT02103478)Phase 3 (NCT03306264) Study population MDS (IPSS low, intermediate-1, intermediate-2, or high risk) and CMML US: MDS (IPSS intermediate-1, intermediate-2, or high-risk)...
查找 NCCN 成员机构: nccn.org/clinical_trials/member_ institutions.aspx. NCCN 对证据和共识的分类:所有推 荐均为 2A 类,除⾮另有说明. 请参⻅ NCCN 对证据和共识的分类. NCCN 优先级分类:所有建议均视为 合理. 请参见 NCCN 优先级分类. 本 NCCN Guidelines® 是作者依据他们对当前所认可治疗方法的...
Temsirolimus, Deforolimus and other mTOR inhibitors are being tested in clinical trials and have shown preclinical efficacy in CMML. EGF receptor inhibitors,... L Bachegowda,O Gligich,I Mantzaris… - 《Journal of Hematology & Oncology》 被引量: 44发表: 2013年 Novel approaches for therapy of ...
Small non-randomized prospective trials have reported activity of AZA [17] and DAC [18] in CMML. Because of the limited efficacy of conventional chemotherapy in CMML-2 and because the AZA-001 trial included some CMML-2 patients, AZA but not DAC was approved in Europe for CMML-2. Again, ...